Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TiNivo-2
2021-000050-26Phase 3Active
- Sponsor
- AVEO Oncology
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Tivozanib + nivolumab with Tivozanib monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Aug 2021; status: active.
02
Drugs
tivozanibnivolumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2021-000050-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000050-26.